Back
Twist Bioscience 10K Form
Buy
66
TWST
Twist Bioscience
Last Price:
44.81
Seasonality Move:
21.79%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2020-08-12 | 10Q | TWST/Twist Bioscience Quarterly |
2020-05-13 | 10Q | TWST/Twist Bioscience Quarterly |
2020-02-10 | 10Q | TWST/Twist Bioscience Quarterly |
2019-12-13 | 10K | TWST/Twist Bioscience Annual |
2019-08-09 | 10Q | TWST/Twist Bioscience Quarterly |
2019-05-02 | 10Q | TWST/Twist Bioscience Quarterly |
Receive TWST News And Ratings
See the #1 stock for the next 7 days that we like better than TWST
TWST Financial Statistics
Sales & Book Value
Annual Sales: | $245.11M |
---|---|
Cash Flow: | $-7.34M |
Price / Cash Flow: | 0 |
Annual Sales: | $8.39 |
Price / Book: | 5.15 |
Profitability
EPS (TTM): | -3.82000 |
---|---|
Net Income (TTM): | $-220.31M |
Gross Margin: | $89.73M |
Return on Equity: | -37.7% |
Return on Assets: | -30.09% |
Twist Bioscience Earnings Forecast
Key Twist Bioscience Financial Ratios
- The Gross Profit Margin over the past 8 years for TWST is 36.61%.
- The Selling, General & Administrative Expenses for TWST have been equal to 77.41% of Gross Profit Margin.
- The Research & Development expenses have been 43.61% of Revenue.
- The Interest Expense is 0.00% of Operating Income.
- The Net Earning history of TWST is -83.48% of Total Revenues.
- Per Share Earnings over the last 8 years have been positive in 4 years.
Twist Bioscience Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NASDAQ |
---|---|
Industry: | Biotechnology |
Sector: | Health Care |
Current Symbol: | TWST |
CUSIP: | 90184D |
Website: | twistbioscience.com |
Debt
Debt-to-Equity Ratio: | 0 |
---|---|
Current Ratio: | 4.91 |
Quick Ratio: | 4.36 |
Price-to-Earnings
Trailing P/E Ratio: | 0 |
---|---|
Forward P/E Ratio: | 0 |
TWST Technical Analysis vs Fundamental Analysis
Buy
66
Twist Bioscience (TWST)
is a Buy
Is Twist Bioscience a Buy or a Sell?
-
Twist Bioscience stock is rated a Buy
The current Twist Bioscience [TWST] share price is $43.14. The Score for TWST is 66, which is 32% above its historic median score of 50, and infers lower risk than normal.